Published in Acta Naturae on April 01, 2013
The mystery of let-7d - a small RNA with great power. Contemp Oncol (Pozn) (2014) 0.89
Association of OPN overexpression with tumor stage, differentiation, metastasis and tumor progression in human laryngeal squamous cell carcinoma. Int J Clin Exp Med (2015) 0.77
Regulation of Human Adenovirus Replication by RNA Interference. Acta Naturae (2015) 0.75
Functional characterization of OPN in human laryngeal squamous cell carcinoma and its xenograft model in nude mice. Int J Clin Exp Med (2015) 0.75
Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth. Exp Hematol Oncol (2014) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Origins and Mechanisms of miRNAs and siRNAs. Cell (2009) 20.77
MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol (2005) 18.94
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev (2003) 17.64
Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet (2002) 17.20
Mechanisms of gene silencing by double-stranded RNA. Nature (2004) 16.82
RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science (2006) 16.00
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell (2006) 11.98
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell (2002) 10.30
MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A (2006) 10.11
Perspective: machines for RNAi. Genes Dev (2005) 9.37
Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell (2005) 9.27
Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol (2003) 7.38
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
The role of RNA interference in heterochromatic silencing. Nature (2004) 4.56
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci U S A (2008) 3.43
Uridine addition after microRNA-directed cleavage. Science (2004) 2.96
Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res (2006) 2.93
Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet (2001) 2.36
Targeted cell entry of lentiviral vectors. Mol Ther (2008) 2.34
Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A (2007) 2.30
Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther (2005) 2.21
RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev (2003) 2.19
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14
Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol (2008) 2.05
A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol (2000) 2.00
Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther (2006) 1.99
Gene delivery by lentivirus vectors. Mol Biotechnol (2007) 1.98
Recent advances in lentiviral vector development and applications. Mol Ther (2010) 1.89
Conversion of pre-RISC to holo-RISC by Ago2 during assembly of RNAi complexes. RNA (2006) 1.85
Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol (2003) 1.73
Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A (2006) 1.71
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells. Mol Ther (2007) 1.63
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol (2001) 1.50
Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc (2006) 1.48
Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther (2003) 1.46
Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood (2002) 1.32
Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med (2006) 1.29
Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther (2009) 1.25
Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Res (2003) 1.22
IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood (2002) 1.21
A novel approach for the construction of multiple shRNA expression vectors. J Gene Med (2007) 1.21
Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther (2007) 1.20
Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype. Gene Ther (2006) 1.17
PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J Virol (2004) 1.15
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther (2011) 1.15
Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther (2006) 1.11
Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. Hum Gene Ther (2003) 1.11
Short-hairpin RNA silencing of endogenous fibroblast growth factor 2 in rat hippocampus increases anxiety behavior. Biol Psychiatry (2011) 1.10
CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology (2005) 1.10
Therapeutic microRNA strategies in human cancer. AAPS J (2009) 1.10
Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther (2007) 1.09
Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther (2007) 1.08
Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo. Blood (2005) 1.05
Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res (2007) 1.02
Production of trans-lentiviral vector with predictable safety. Methods Mol Med (2003) 1.02
Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions. J Gene Med (2007) 1.01
Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nat Med (2003) 1.00
Use of HIV as a gene transfer vector. Acta Biochim Pol (2009) 1.00
Strategies for targeting lentiviral vectors. Curr Gene Ther (2008) 0.99
Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res (2009) 0.99
Surface-engineering of lentiviral vectors. J Gene Med (2004) 0.99
Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes. Cell Cycle (2011) 0.98
Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J Gene Med (2008) 0.93
Structural domains in RNAi. FEBS Lett (2005) 0.92
Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression. Antivir Ther (2003) 0.91
Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. ACS Chem Biol (2010) 0.90
siRNAs: potential therapeutic agents against hepatitis C virus. Virol J (2011) 0.87
Development of resistance to RNAi in mammalian cells. Ann N Y Acad Sci (2005) 0.87
Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5. Mol Ther (2010) 0.85
[Modulation of activated oncogene c-kit expression with RNA-interference]. Mol Biol (Mosk) (2012) 0.85
Production of lentiviruses displaying ''early-acting'' cytokines for selective gene transfer into hematopoietic stem cells. Methods Mol Biol (2008) 0.85
Targeting lentiviral vector to specific cell types through surface displayed single chain antibody and fusogenic molecule. Virol J (2010) 0.84
[Lentiviral vectors]. Mol Biol (Mosk) (2008) 0.82
Genetic screening of new genes responsible for cellular adaptation to hypoxia using a genome-wide shRNA library. PLoS One (2012) 0.82
Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule. Biotechnol Bioeng (2009) 0.81
Silencing the myotrophin gene by RNA interference leads to the regression of cardiac hypertrophy. Am J Physiol Heart Circ Physiol (2009) 0.79
Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm Res (2009) 0.78
A Comparison of Target Gene Silencing using Synthetically Modified siRNA and shRNA That Express Recombinant Lentiviral Vectors. Acta Naturae (2009) 0.78
Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett (1988) 0.89
Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition. Biochemistry (Mosc) (2010) 0.89
The coding region of the human c-mos pseudogene contains Alu repeat insertions. Gene (1984) 0.87
Activation of c-Ki-ras gene in human pancreatic cancer. Jpn J Cancer Res (1985) 0.86
[Modulation of activated oncogene c-kit expression with RNA-interference]. Mol Biol (Mosk) (2012) 0.85
[Activated leukemic oncogenes responsible for neoplastic transformation of hematopoietic cells]. Mol Biol (Mosk) (2010) 0.85
Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs. Acta Naturae (2013) 0.83
[Downregulation of activated leukemic oncogenes AML1-ETO and RUNX1(K83N) expression with RNA-interference]. Mol Biol (Mosk) (2010) 0.83
[Lentiviral vectors]. Mol Biol (Mosk) (2008) 0.82
Human nucleotide sequences related to the transforming gene of a murine sarcoma virus: studies with cloned viral and cellular DNAs. Gene (1982) 0.82
Replication protein A modulates the activity of human telomerase in vitro. Biochemistry (Mosc) (2009) 0.81
[Expression of FLT3-ITD oncogene confers mice progenitor B-cells BAF3 sensitivity to the ribonuclease binase cytotoxic action]. Mol Biol (Mosk) (2013) 0.80
Deamination of 5-methylcytosine residues in Mammalian cells. Acta Naturae (2009) 0.80
Transforming activity of the c-Ha-ras oncogene having two point mutations in codons 12 and 61. Jpn J Cancer Res (1985) 0.79
Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System. Acta Naturae (2011) 0.79
[Role of N-linked glycans in HCV glycoprotein E1 in the folding of structural proteins and formation viral particles]. Mol Biol (Mosk) (2013) 0.78
A Comparison of Target Gene Silencing using Synthetically Modified siRNA and shRNA That Express Recombinant Lentiviral Vectors. Acta Naturae (2009) 0.78
Nucleotide sequence of the BamHI repetitive sequence, including the HindIII fundamental unit, as a possible mobile element from the Japanese monkey Macaca fuscata. J Mol Evol (1986) 0.78
Polymorphic changes of cell phenotype caused by elevated expression of an exogenous NEU proto-oncogene. Oncogene (1990) 0.77
The use of syngeneic cells producing human somatotropic hormone (hSTH) for immunization of mice and development of hybridomas. Hybridoma (1990) 0.77
[Replication-competent γ-retrovirus Mo-MuLV expressing green fluorescent protein gene as an efficient tool for screening of inhibitors of retroviruses that use heparan sulfate as the primary cell receptor]. Mol Biol (Mosk) (2012) 0.76
RNA interference and deep sequencing as tools for identifying new genes involved in leukemogenesis. Dokl Biochem Biophys (2013) 0.75
Cystathionase: high-performance liquid chromatography. Molecular cloning in lambda gt11. Nonradioactive immunodetection of fusion protein. Biochimie (1989) 0.75
[Universal modular system for in vitro screening of potential inhibitors of HIV-1 replication]. Mol Biol (Mosk) (2015) 0.75
[Characterization of new splicing mutation in steroid 21-hydroxylase gene]. Bioorg Khim (2012) 0.75
Human genome: proto-oncogenes and proretroviruses. Folia Biol (Praha) (1985) 0.75
[Functional characterization of two novel splicing mutations in glucokinase gene in monogenic diabetes MODY2]. Mol Biol (Mosk) (2015) 0.75
[Novel bidirectional promoter from human genome]. Mol Biol (Mosk) (2011) 0.75
[Nonfarmacological treatment of erectile dysfunction in obese patients]. Urologiia (2010) 0.75
[Dynamics of penetration of "solid" nanoconstructions based on double-stranded DNA complexed with gadolinium into CHO cells]. Mol Biol (Mosk) (2014) 0.75
[Baculovirus vectors for efficient gene delivery and expression in mammalian cells]. Mol Biol (Mosk) (2010) 0.75
Benzophenone derivatives of pyrimidines as effective non-nucleoside inhibitors of wild-type and drug-resistant HIV-1 reverse transcriptase. Dokl Biochem Biophys (2013) 0.75